



台美藥劑協會

Taiwanese American Association of
Pharmaceutical Sciences (TAAP)



Yiu-Lian Fong, PhD, MBA

Global Head, Scientific
Innovation, Diagnostics,
Johnson & Johnson
Innovation

Topic: Dx Innovation in the
Era of Precision Medicine
and Big Data: Opportunities
and challenges

Yiu-Lian is the Global Head for Diagnostic Innovation, Research and Early Development at Johnson & Johnson Innovation. Yiu-Lian has global responsibility for identifying, assessing and accelerating the development of breakthrough diagnostic technologies and solutions to help drive precision medicine and Johnson & Johnson's World Without Disease initiative.

Prior to joining Johnson & Johnson Innovation, Yiu-Lian was the Divisional Vice President for R&D at Abbott Molecular. In this position, she was responsible for R&D strategic oversight, menu expansion, advancing R&D pipelines including the development of next generation molecular diagnostic platform technologies. Previously, she was the Executive Director of Molecular Diagnostics and Companion Diagnostics Development at Novartis Oncology. Yiu-Lian brings a broad and extensive background in the pharmaceutical and biotechnology industries including experience in technology and product development, blood testing/screening,

2018 TAAP SYMPOSIUM

vaccines and IVD Immuno and molecular diagnostics, as well as therapeutic drug/vaccine development.

Yiu-Lian received her M.S. in Life Sciences from The National Tsing Hua University in Taiwan, and her MBA from the University of Massachusetts, Amherst. She earned her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and was a post graduate fellow at Johns Hopkins University. Yiu-Lian also has 25 publications in peer review journals and several issued patent applications.